Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Prediction of postoperative intensive care unit admission with artificial intelligence models in non-small cell lung carcinoma
1
Zitationen
8
Autoren
2025
Jahr
Abstract
BACKGROUND: There is no standard practice for intensive care admission after non-small cell lung cancer surgery. In this study, we aimed to determine the need for intensive care admission after non-small cell lung cancer surgery with deep learning models. METHODS: The data of 953 patients who were operated for non-small cell lung cancer between January 2001 and 2023 was analyzed. Clinical, laboratory, respiratory, tumor's radiological and surgical features were included as input data in the study. The outcome data was intensive care unit admission. Deep learning was performed with the Fully Connected Neural Network algorithm and k-fold cross validation method. RESULTS: The training accuracy value was 92.0%, the training F1 1 score of the algorithm was 86.7%, the training F1 0 value was 94.2%, and the training F1 average score was 90.5%. The test sensitivity value of the algorithm was 67.7%, the test positive predictive value was 84.0%, and the test accuracy value was 85.3%. Test F1 1 score was 75.0%, test F1 0 score was 89.5%, and test F1 average score was 82.3%. The AUC in the ROC curve created for the success analysis of the algorithm's test data was 0.83. CONCLUSIONS: Using our method deep learning models predicted the need for intensive care unit admission with high success and confidence values. The use of artificial intelligence algorithms for the necessity of intensive care hospitalization will ensure that postoperative processes are carried out safely using objective decision mechanisms.
Ähnliche Arbeiten
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.792 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.470 Zit.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.861 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.979 Zit.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · 9.414 Zit.